Hepatitis C virus (HCV) nonstructural 3 (NS3) serine protease disrupts important cellular antiviral signaling pathways and plays a pivotal role in the proteolytic maturation of the HCV polyprotein precursor. This recent discovery has fostered the search for NS3 protease inhibitors. However, the enzyme's unusual induced fit behavior and peculiar molecular architecture have imposed considerable obstacles to the development of small molecule inhibitors. In this article, we demonstrate that such unique induced fit behavior and the chymotrypsin-like catalytic domain can provide the structural plasticity necessary to generate proteinbased inhibitors of the NS3 protease. We took advantage of the macromolecular scaffold of a Drosophila serpin, SP6, which intrinsically supports chymotrypsin-like enzyme inhibition, to design a novel class of potent and selective inhibitors. We show that altering the SP6 reactive site loop (RSL) resulted in the development of the first effective (K i of 34 nM) and selective serpin, SP6 EVC/S , directed at the NS3 protease. SP6 EVC/S operates as a suicide substrate inhibitor, and its partitioning between the complex-forming and proteolytic pathways for the NS3 protease is HCV NS4A cofactor-dependent and -specific. Once bound to the protease active site, SP6 EVC/S partitions with equal probability to undergo proteolysis by NS3 at the C-terminal site of the engineered RSL, (P 6 )GluIle-(P 4 )Val-Met-Thr-(P 1 )Cys-2-(P 1 )Ser, or to form a covalent acyl-enzyme complex characteristic of cognate protease-serpin pairs. Our results also reveal a novel cofactor-induced serpin mechanism of enzyme inhibition that could be explored for developing effective and selective inhibitors of other important induced fit viral proteases of the Flaviviridae family such as the West Nile virus NS3 endoprotease.
Hepatitis C virus (HCV)
1 infection has reached worldwide epidemic proportions, with Ͼ3% of the world population infected and 3-4 million people newly infected each year (1) . The clinical significance of HCV and the need to rapidly identify new therapeutic approaches has resulted in intensive study of the molecular properties of this virus; yet, thus far, no efficient therapy or vaccine exists (1, 2) . Moreover, although considerable progress has been made in understanding HCV biology (3, 4) , the molecular mechanisms by which HCV induces liver cirrhosis, fibrosis, and hepatocellular carcinoma remain unclear (1) . The discovery that HCV nonstructural 3 (NS3) protease may be involved in the modulation of important host cell functions (5) , in addition to its role in the maturation of the viral polyprotein precursor (NS3-NS5) (6) , has fostered the search for NS3 protease inhibitors (2, 7) .
The NS3 protease is an induced fit serine protease that adopts a chymotrypsin-like fold (8) . The action of a virusencoded protein cofactor, NS4A, is required for some but not all of the NS3-dependent proteolytic cleavage events in vitro (9) and ex vivo (10, 11) . The commonly accepted model of action for the NS3 protease suggests that the protease undergoes an induced fit in the presence of the NS4A cofactor (12, 13) and substrate/inhibitor (14) . Intercalation of NS4A into the N-terminal domain of NS3 results in a rearrangement of the active site, consistent with the observed increase in the catalytic efficiency reported for the recombinant NS3/4A protease (15, 16) .
The proposed mechanism of substrate-induced protease activation provides a framework to explain how the NS3 protease could be partially active even in the absence of the NS4A cofactor (15, 16) . Unlike proteases of the long chain subfamily (17) , such as human elastase, NS3 protease has short loops resulting in a featureless, shallow, and solvent-exposed substrate binding site, a feature that makes development of small molecule inhibitors difficult (2, 7) . The interaction between the NS3 protease and its substrates is characterized by a series of weak contacts that extend over 10 amino acid residues, requires a cysteine in the P 1 position, and relies on high charge densities (17) . Thus, substrate recognition by the NS3 protease is more reminiscent of the protein-protein interactions found in an enzyme-protein inhibitor pair than of a "conventional" enzyme-substrate complex (12, 17) .
In this article, we hypothesized that the bioengineering of a naturally occurring serine protease inhibitor (serpin) scaffold could provide a new approach to developing high affinity, selective NS3 protease inhibitors (18, 19) . Serpins differ from non-serpin inhibitors in that they require a large inhibitor conformational change in order to trap proteases in an irreversible complex (20) . The conformational change is initiated by the reaction of the active serine of the protease with the reactive site loop (RSL) of the serpin that results in a covalent species involving an acyl ester linkage to the ␥O of the protease active site serine. This cleaves the RSL, which then moves 71 Å to the opposite pole of the serpin, taking the tethered protease with it (20, 21) .
We selected a Drosophila serpin, SP6, to serve as a prototype of the macromolecular inhibitor scaffold, because SP6 has been shown to inhibit chymotrypsin-like proteases (22) . We show that engineering of the RSL of SP6 resulted in the development of SP6 EVC/S , the first selective and effective serpin directed at the NS3 protease. SP6 EVC/S operates as a suicide substrate inhibitor with the slow tight binding mechanism characteristic of serpin molecules. Partitioning between the covalent serpin acyl-enzyme complex-forming and proteolytic pathways for NS3 protease is both HCV NS4A cofactor-and serpin-dependent, supporting the recent model of cofactor-and substrate-induced NS3 activation as a mechanism of narrow specificity (23) .
EXPERIMENTAL PROCEDURES
Materials-pyroGlu-Arg-Thr-Lys-Arg-4-methylcoumaryl-7-amide (pERTKR-MCA) was obtained from Bachem, trypsin (EC: 3.4.21.4) from Sigma, and anti-FLAG from Affinity Bioreagents.
Synthesis of Peptidyl Analogs-All peptides were prepared by solid phase synthesis with the Fmoc (N-(9-fluorenyl)methoxycarbonyl) methodology using a multiple automated peptide synthesizer (24) . Peptide purity and composition was demonstrated by reverse phase HPLC (RP-HPLC), matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (MS), and amino acid analysis (University of Toronto Advanced Protein Technology Center). The following peptides were used in this study: Ac-KKKGSVVIVGRIILSGR-NH 2 (HCV-Pep4A); Ac-KKKGSVVVVGRIILSGR-NH 2 (HCV-I25V); Ac-KKK-GSVVIVGRWILSGR-NH 2 (HCV-I29W); Ac-KKKGSVVVVGRWILSGR-NH 2 (HCV-I25V/I29W); Ac-KKKGSLVVVTSWVVNGN-NH 2 (GBVAPep4A); Ac-KKKGATCVRRCWSITSV-NH 2 (GBVB-Pep4A); and Ac-KKKGSLVVVTDWDVKGG-NH 2 (GBVC-Pep4A). Full details of the synthesis and biochemical characterization of Abz-Asp-Asp-Ile-Val-ProCys-Ser-Met-Ser-Tyr(NO 2 )-Thr-NH 2 (IQFS-1) and (fluorescein)-Asp-DGlu-Leu-Ile-Cha-Cys-Pro-Cha-Asp-Leu-NH 2 (PepInh-1) (where Cha is cyclohexylalanine) will be presented elsewhere. Stock peptide solutions (10 mM) were prepared in Me 2 SO and stored at Ϫ20°C.
The His-tagged HCV NS3 Serine Protease and His/FLAG-tagged SP6 Variants-His-tagged NS3 expression plasmid encoding the N-terminal 181 amino acids of NS3 was kindly provided by Dr. N Kakiuchi, National Institute of Bioscience and Human Technology of Japan (25) . His/FLAG-tagged SP6 was prepared from pET21a-SP6 (22) by standard PCR methods using an oligonucleotide primer encoding the FLAG epitope (Fig. 1) . Desired changes in the RSL of parental SP6 were introduced using the QuikChange site-directed mutagenesis method (Stratagene). Primers incorporating the desired changes were synthesized by Alpha DNA Inc. Multiple amino acid changes were introduced by sequential rounds of mutagenesis using newly synthesized SP6 variants as template. Introduction of the desired changes was confirmed by sequencing (Sheldon Biotechnology Center, McGill University, Montreal, Canada).
Expression and Purification of HCV NS3 and Recombinant SP6 Variants-Recombinant NS3 protease and SP6 variants were expressed in the cytosol of bacteria (Escherichia coli BL21 pLysS) and purified as reported previously (18) by nickel binding interaction chromatography (HiTrap Columns; Amersham Biosciences) using an AKTApurifier FPLC system (Amersham Biosciences). Protein purity and composition were demonstrated by RP-HPLC (18), MALDI-TOF MS ( Fig. 1) (University of Victoria-Genome British Columbia Proteomics Facility), Western blot (Fig. 2) , and amino acid analysis (University of Toronto). Proteins were aliquoted, snap frozen, and stored at Ϫ86°C.
Enzymatic Assays-The enzyme assay data were obtained by using a SpectraMax Gemini XS spectrofluorometer equipped with a temperature-controlled 96-well plate reader (Molecular Dynamics) using excitation/emission wavelengths of 370/460 nm to measure release of 7-amido-4-methylcoumarin (AMC) (16) or 320/420 nm to measure the fluorescence signal of Abz-DDIVPC-OH (26) . Trypsin assays were performed using pyroGlu-Arg-Thr-Lys-Arg-4-methylcoumaryl-7-amide as a fluorogenic substrate (27) , whereas a novel intramolecularly quenched fluorogenic peptide substrate (IQFS-1), based on the fluorescence energy transfer between the donor/acceptor couple (Abz and Tyr(NO 2 )), was used for NS3 protease (26) . Trypsin assays were performed at 30°C in 100 mM Hepes (pH 7.3) containing 1 mM CaCl 2 and 0.5% Triton X-100. NS3 protease assays were performed at 30°C in 50 mM Hepes (pH 7.3), 1 mM dithiothreitol, 100 mM NaCl, and 0.1% Triton X-100. An NS3/4A protease heterocomplex was generated by preincubating NS3 with a saturating amount of HCV-Pep4A (7 M) for 15 min at 30°C (16) .
SDS-PAGE of Protease-Serpin Reactions-Reactions were performed under the buffer conditions for enzyme assays. Samples were collected at 1 h (unless otherwise noted), mixed immediately with reduced SDSloading buffer at 95°C, and heated for 10 min. SDS-gel electrophoresis (18) was performed in a 10% gel, and the protein was visualized by Coomassie Blue or analyzed by Western blotting using anti-FLAG antibody following transfer to nitrocellulose (18, 19) . Western blots were visualized directly using the VersaDoc imaging system (Bio-Rad). The resulting digital images were quantified using Quantity One software (Bio-Rad).
Determination of the RSL Cleavage Site and Covalent Serpin-Protease Complex Formation by MS-SP6
C/S and SP6 EVC/S (0.2 M) were incubated with NS3/4A (2 M:7 M) for 1 h at 30°C. Reactions were stopped with an aqueous 0.
) was chosen so that the reaction products were generated at sufficient levels to be detected by MALDI-TOF MS (University of Victoria). Alternatively, after completion, products were resolved on a 10% SDS gel. The high molecular weight complex band (EI*) was visualized with Coomassie Blue and excised from the gel. Trypsin digestion of the protein was performed by in-gel cleavage (28) . The resulting peptide fragments were recovered by a series of extractions using 10% formic acid, and the mixture was resolved by RP-HPLC. Identification of each peptidyl fragment was performed using a quadruple TOF MS (University of Victoria).
Stoichiometry of Inhibition (SI) and Determination of K i -Values
for SI and K i were determined as described previously (18) using active-site titrated NS3/4A protease. The active concentration of NS3/4A protease was determined by active site titration with PepInh-1, a novel tightbinding reversible inhibitor of NS3/4A protease (K i ϭ 2.8 Ϯ 0.2 nM). 2 Subsequent titrations were performed by pre-incubating each serpin variant with NS3 or NS3/4A for 30 min at 30°C and adding increasing amounts of inhibitors to a fixed amount of protease. The residual protease activity was determined by the addition of IQFS-1 (100 M).
[E 0 ] and K i were obtained as described previously (18, 29) . Measurements were also made using the progress curve method for the reaction started with enzyme (18) .
RESULTS
Engineering Drosophila SP6 Scaffold to Target the HCV NS3 Viral Protease-Because previous studies have demonstrated that SP6 architecture can inhibit chymotrypsin-like serine proteases (22), we selected this novel Drosophila serpin scaffold to bioengineer an inhibitor directed at the NS3 protease. The design of the SP6-RSL was based on a quantitative kinetic analysis performed with IQFSs based on NS3-dependent cleavage sites of the HCV polyprotein. 3 We observed that the binding energy for the substrate is derived from a series of weak interactions distributed along an extended contact surface (P 6 -P 4 Ј) (30) . The major determinants of substrate recognition include conserved residues in (P 1 )Cys, (P 1 Ј)Ser, and (P 6 )Glu positions. P 3 , P 4 and P 4 Ј residues also contribute to efficient substrate recognition, although less dramatically. The RSL sequence of SP6 variants prepared in this study is shown in Fig. 1 and includes single or multiple mutations introduced to optimize the interactions between the RSL of SP6 and the substrate binding sites of NS3 (S 6 -S 1 Ј) (30) .
Selective Inactivation of HCV NS3/4A Protease Activity by Bioengineered SP6
EVC/S -We screened for serpin inhibitory activity by incubating the SP6 variants with trypsin or NS3/4A before adding the appropriate substrate ( Fig. 2A) . Although the native SP6 inhibited trypsin completely, it was not effective against NS3/4A protease activity ( Fig. 2A) . As predicted, engineering the SP6-RSL to include all the key molecular determinants needed for optimum recognition by the viral protease generates a serpin (SP6 EVC/S ) that efficiently inactivates NS3/4A protease activity ( Fig. 2A) . Importantly, optimizing the RSL of SP6 to target NS3 also resulted in a loss of trypsin inhibition. SP6 C/S , whose RSL is lacking the P 4 and P 6 mutations, inhibited both trypsin and NS3. The inhibition of trypsin was less efficient and did not involve a classical serpin mechanism (no apparent SDS-heat stable complex; data not shown). Substitution of the serine residue in P 1 Ј position of SP6 EVC/S by a proline residue (SP6 EVC/P ) resulted in a loss of inhibitory activity against NS3/4A protease ( Fig. 2A) . This was a surprising result, because a similar substitution in a synthetic peptidyl substrate based on the HCV NS5A/5B junction resulted in a competitive inhibitor of NS3 (31) . This first survey of inhibitory activity of the SP6 variants confirmed the potential of SP6 as a scaffold to design NS3 specific inhibitors.
HCV-Pep4A Is Required for Specific Interaction of HCV NS3 Protease with Serpin-The influence of the HCV-Pep4A (NS4A cofactor, residues 21-34; Fig. 5 ) on the mechanism of inhibition of NS3 protease by the SP6 variants was evaluated. SP6 variants were incubated with NS3 or NS3/4A, and the reactions were analyzed by Western blot (Fig. 2B) . Incubation of each serpin in the absence of NS3 protease showed a single ϳ44-kDa protein (Fig. 2B, lanes 1, 4, 7, 10, and 13) , which corresponds to the predicted mass of the SP6 variants (Fig. 1) . Including HCV-Pep4A in the incubation with NS3 resulted in a shift of SP6 C/S and SP6 EVC/S (Fig. 2B, lanes 6, 9, and 12 ) to a single high M r band (ϳ70 kDa) corresponding to the predicted molecular masses of serpin-NS3 complexes (64.4 kDa). Native SP6, SP6 C , and SP6 EVC/P could not form a complex with NS3/4A (less than 2% with SP6 C ), and the SP6 variants were not cleaved, indicating that these variants are not effective inhibitors of NS3 (Fig. 2B, lanes 3, 6, and 15) . In contrast, the EI* complex observed with SP6 C/S and SP6 EVC/S was associated with the presence of the cleaved forms (I c ϳ 39 kDa) of the serpin (Fig. 2B, lanes 9, 12) . These data indicate that SP6 C/S and SP6 EVC/S , in the presence of HCV-Pep4A, can interact with the protease. We concluded that HCV-Pep4A is required for efficient formation of SDS-stable complexes between NS3 protease and SP6
C/S or SP6 EVC/S .
HCV NS3 Protease Forms a Stable Covalent Acyl-Enzyme Complex with SP6
EVC/S -MS analysis was used to identify the high M r band resolved on SDS-PAGE for the NS3/4A-SP6 EVC/S reaction (Fig. 2B, lane 12 ) . These results are consistent with the idea that the high M r band detected by Western blot is an SDS-heat stable serpin acylenzyme complex.
MALDI-MS was used to demonstrate the formation of a covalent serpin acyl-enzyme complex between SP6 EVC/S and NS3 protease. MS analysis of the NS3/4A-SP6 EVC/S reaction performed in optimized conditions to yield maximum amounts of complexes revealed the presence of stable covalent species with an observed mass of 64308.88 (Fig. 3B) . The calculated mass for the NS3-SP6 EVC/S serpin-protease complex is 64427.41 (relative error 0.18%). Other species detected included the liberated SP6 EVC/S N-terminal (39845.62) (Fig. 3B ) and C-terminal (3932.05) (Fig. 3A) fragments, native NS3 protease (24338.00) (Fig. 3B) , and HCV-Pep4A (1851.31) (Fig. 3A) . Thus, MS analysis of the NS3/4A-SP6 EVC/S reaction revealed products consistent with the formation of a covalent complex (inhibitor pathway) characteristic of serpin-enzyme interactions and cleavage of the engineered RSL at the P 1 position (substrate pathway) (20) . temporal relationship between complex formation and inhibition of NS3 protease activity was examined. The rate of complex formation (k obs ) of NS3/4A protease by SP6 C/S and SP6 EVC/S was examined by SDS-PAGE, and the value was determined as described previously (32) (Fig. 4) . NS3 or NS3/4A was combined with each of the serpin variants, and complex formation was measured at various time points (Fig. 4,  A and B) . The k obs with NS3/4A protease for SP6 EVC/S (3.3 Ϯ 0.4 ϫ 10 Ϫ2 s Ϫ1 ) is ϳ3ϫ more rapid than the value estimated for SP6 C/S (1.2 Ϯ 0.2 ϫ 10 Ϫ2 s Ϫ1 ). In the absence of HCV-Pep4A, the rate of serpin-protease complex formation was much slower (SP6 EVC/S -NS3, 50% complete (t1 ⁄2 ) at 4 h; SP6 C/S -NS3 Ͻ 1% at 4 h; data not shown). By comparison, the t1 ⁄2 values of SP6 EVC/S -NS3/4A and SP6 trypsin complex formation were 85 s (Fig. 4B) and 20 s (data not shown), respectively. Typical of serpinenzyme interactions, the inhibition of NS3/4A by SP6 C/S (Fig.  4C ) and SP6 EVC/S (Fig. 4D ) obeyed slow binding inhibition kinetics as indicated by biphasic plots in which maximal inhibition was achieved more rapidly with increasing concentrations of serpin (18) . The serpin-enzyme complexes were kinetically trapped, because no NS3 protease activity was recovered for up to 3 h (Fig. 4, C and D) . These results confirm the SDS-PAGE analysis (Fig. 4, A and B, insets) and support the formation of covalent complexes demonstrated by MS analyses (Fig. 3B) .
SP6 EVC/S Inhibits HCV NS3/4A Protease by the Slow Tight Binding Mechanism Characteristic of Serpin Molecules-The

SP6 EVC/S Is a Tight Binding Titrant of the HCV NS3/4A
Protease-After formation of the serpin/enzyme acyl intermediate (EIЈ) (20) , serpins may either be cleaved and released (I c ) or trap the enzyme in a kinetically stable SDS-resistant complex (EI*) (Fig. 4B, inset) (20) . The relative flux of a serpin through these pathways reflects its efficiency as an inhibitor for a given enzyme and is described as the stoichiometry of inhibition (20) . SI is defined as the ratio of moles of serpin needed to inhibit 1 mol of protease (20) . Titration experiments were performed to determine the SI for NS3/4A-SP6 C/S and NS3/4A-SP6 EVC/S (18, 29) . The concentration of NS3/4A ([E 0 ]) was determined by titrating the enzyme activity with PepInh-1 (data not shown). In a parallel analysis, NS3/4A activity was titrated with SP6 C/S (Fig. 4E) or SP6 EVC/S (Fig. 4F) . Regression analysis of residual NS3/4A activity as a function of [I 0 ]/[E 0 ] shows that SP6 C/S inhibits NS3 with an SI of ϳ4 (3.8), whereas SP6 EVC/S inhibits with an SI of ϳ2 (2.1). This means that, after binding to the active site of NS3, SP6
EVC/S partitions with equal probability between the substrate and the inhibition pathways (20) . Analysis of the titrations by curve fitting (Fig. 4,  E and F 
SP6
C/S and 34 Ϯ 5 nM for NS3/4A-SP6 EVC/S . These results indicated that SP6 EVC/S is a tight binding titrant of the NS3/4A protease operating as a suicide substrate inhibitor.
HCV NS4A Is an Obligate Cofactor for HCV NS3 Protease Inhibition by SP6
EVC/S -We evaluated the stimulatory effects of other NS4A functional homologues from the Flaviviridae family (33) . We synthesized three NS4A peptides containing the putative minimal activating NS4A sequence (amino acids 22-33) of GBVA, GBVB, and GBVC (34) . Analysis of the products of the NS3/4A/serpin reactions showed that only HCVPep4A significantly enhanced complex formation (Fig. 5B,  lanes 1 and 6) . As a control, we measured the stimulatory effects of the NS4A peptides in trans-cleavage reactions using IQFS-1. The results showed that cleavage strictly depends on the addition of HCV-Pep4A (Fig. 5B, left panel) . No other NS4A analog could activate NS3 protease activity even when used in 5-fold excess of the saturating concentration for HCV-Pep4A (data not shown). Thus, the cofactor dependence for complex formation parallels the changes seen for enzymatic activity, for which only the presence of HCV-Pep4A increases hydrolysis rates.
Role of Ile 25 and Ile 29 of the NS4A on Serpin Acyl-Enzyme Complex Formation-Comparison of the primary sequences of Flavivirus NS4A functional homologues with several Hepacivirus strains demonstrates that hydrophobic amino acids are highly conserved at positions 25 and 29 of the central region of NS4A protein (data not shown). Although these two residues are strictly conserved within isolates of the same genus, they differ markedly across the Hepacivirus and Flavivirus strains (Fig. 5A) . We synthesized three HCV-Pep4A variants by substituting residues at positions 25 (HCV-I25V), 29 (HCV-I29W), and 25 and 29 (HCV-I25V/I29W) for the corresponding residues conserved in NS4A of GBVs. Analysis of the products of the NS3/4A/serpin reactions showed that mutation at Ile 25 or Ile 29 had an important effect on SP6 C/S -NS3 complex formation with cofactor activity values reduced to ϳ56.5% (HCV-I25V) and 20.3% (HCV-I29W) of wild-type levels (Fig. 5C, right panel) . The double mutations at Ile 25 and Ile 29 (HCV-I25V/I29W) had a more dramatic effect, reducing activity to only 3.6% of wildtype. In contrast, the effect of the individual mutations (Ile 25 or Ile 29 ) was less pronounced with the SP6 EVC/S variant (87.1% and 69.7%), with complete reduction of the NS4A-mediated complex activation observed only when the reaction was performed with the double mutant, HCV-I25V/I29W (Fig. 5C,  right panel) . It should be noted that SP6 EVC/S can form an acyl-enzyme complex via an NS4A-independent mechanism (30.6% of wild-type control), supporting a plausible role for the serpin itself in enzyme activation (Fig. 5C, right panel) .
The effects that these substitutions in the HCV-Pep4A impart on the active site of NS3 protease were investigated using IQFS-1 (Fig. 5C, left panel) . We found that substituting residues 25 and 29 individually with the corresponding residues from GBV NS4A resulted in a substantial decrease in the NS3/4A endoproteolytic activity (HCV-I25V, 51.8%; HCV-I29W, 24.5%) (Fig. 5 C, left panel) . The double mutant of NS4A cofactor peptide, HCV-I25V/I29W, had little cofactor activity (15.3%) (Fig. 5C, left panel) . The requirement of the same functional domain and hydrophobic amino acids of NS4A for each trans-processing activity of NS3 (serpin or substrate recognition and catalysis) indicated a critical role for NS4A in these two biochemical pathways and a complex interplay between the cofactor, viral protease, and serpin. This is further supported by the important increase in K i (127 Ϯ 13 nM) and SI (8.3 Ϯ 0.6) determined for NS3/SP6 EVC/S in the presence of HCV-I29W (data not shown). Taken together, the results of this study indicate the critical requirement of a fully activated heterodimeric protease (NS3/4A) for SP6 EVC/S to effectively form a complex with and inhibit the NS3 protease.
DISCUSSION
This article presents the design and characterization of a novel class of potent and selective HCV NS3 protein inhibitors. We selected a novel Drosophila serpin, SP6, as a prototype of a protein inhibitor scaffold because it has been shown to inhibit chymotrypsin-like proteases (22) . Engineering of the RSL of SP6 resulted in the development of SP6 EVC/S , the first selective and effective serpin directed at the NS3 protease. Kinetic studies have shown that SP6 EVC/S inhibits NS3 by the slow tight binding mechanism typical of serpins and operates as a suicide substrate inhibitor. Biochemical analysis of the serpin mechanism of NS3 protease inhibition revealed that HCV NS4A is an obligate cofactor for enzyme inhibition by SP6 EVC/S . 25 and Ile 29 of the NS4A on serpin acyl-enzyme complex formation. The effect of HCV-Pep4A variants (7 M) on NS3 protease activity and complex formation with SP6 variants were analyzed as described above. The data are averages of duplicate samples and are representative of three independent experiments.
